
Pear Therapeutics
Founded Year
2013Stage
Asset Sale | AssetsPurchasedTotal Raised
$334.94MRevenue
$0000About Pear Therapeutics
Pear Therapeutics focuses on developing and commercializing software-based medicines, known as prescription digital therapeutics (PDTs), within the healthcare sector. The company offers clinically validated software-based therapeutics designed to provide better outcomes for patients, engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear Therapeutics primarily serves the healthcare industry, focusing on patients with substance use disorder, opioid use disorder, and chronic insomnia. It was founded in 2013 and is based in Boston, Massachusetts. In April 2023 Pear Therapeutics filed for bankruptcy.
Loading...
Loading...
Research containing Pear Therapeutics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Pear Therapeutics in 3 CB Insights research briefs, most recently on Jan 25, 2024.

Jan 25, 2024 report
State of Digital Health 2023 ReportExpert Collections containing Pear Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Pear Therapeutics is included in 3 Expert Collections, including Digital Health 50.
Digital Health 50
300 items
The most promising digital health startups transforming the healthcare industry
Digital Health
11,422 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Precision Medicine Tech Market Map
160 items
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Pear Therapeutics Patents
Pear Therapeutics has filed 14 patents.
The 3 most popular patent topics include:
- cognitive behavioral therapy
- monoclonal antibodies
- psychiatric diagnosis

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/11/2023 | 2/27/2024 | Data security, Monoclonal antibodies, Cryptographic hash functions, Health informatics, Medical terminology | Grant |
Application Date | 4/11/2023 |
---|---|
Grant Date | 2/27/2024 |
Title | |
Related Topics | Data security, Monoclonal antibodies, Cryptographic hash functions, Health informatics, Medical terminology |
Status | Grant |
Latest Pear Therapeutics News
Aug 13, 2025
global psychiatric digital biomarkers market size was worth around USD 6.40 billion in 2024 and is predicted to grow to around USD 26.60 billion by 2034,(CAGR) of roughly 19.50% between 2025 and 2034.” — Deepak Rupnar PUNE, MAHARASHTRA, INDIA, August 13, 2025 / EINPresswire.com / -- ✖ Global Psychiatric Digital Biomarkers Market: Size, Share, Trends, and Forecast Analysis (2024–2034) 1. Executive Summary The global psychiatric digital biomarkers market Size was valued at $6.40 billion in 2024 and is projected to reach approximately $26.60 billion by 2034, expanding at a compound annual growth rate (CAGR) of 19.50 % between 2025 and 2034. Access key findings and insights from our Report in this sample - https://www.zionmarketresearch.com/sample/psychiatric-digital-biomarkers-market Psychiatric digital biomarkers are objective, quantifiable physiological and behavioral data collected via digital devices (e.g., smartphones, wearable sensors, connected apps) that help in the diagnosis, monitoring, and treatment of mental health conditions. The growth is driven by increasing prevalence of psychiatric disorders, advancements in AI-based digital health tools, rising adoption of telepsychiatry, and the demand for continuous patient monitoring. 2. Market Overview 2.1 Definition & Scope A psychiatric digital biomarker refers to digitally measured data points that provide insights into a patient's mental health status. Examples include speech patterns, facial expression changes, motor activity, sleep cycles, and social interaction metrics. These biomarkers are increasingly used for conditions such as depression, anxiety disorders, schizophrenia, bipolar disorder, and PTSD. 2.2 Market Dynamics Snapshot 2024 Market Size: $6.40 billion 2034 Forecast Size: $26.60 billion CAGR (2025–2034): 19.50 % Key Insights: As per the analysis shared by our research analyst, the global psychiatric digital biomarkers market is estimated to grow annually at a CAGR of around 19.50% over the forecast period (2025-2034) In terms of revenue, the global psychiatric digital biomarkers market size was valued at around USD 6.40 billion in 2024 and is projected to reach USD 26.60 billion by 2034. The psychiatric digital biomarkers market is projected to grow significantly due to the increasing prevalence of mental health disorders, advancements in mobile health and wearable technology, and the growing adoption of machine learning (ML) and artificial intelligence (AI). Based on type, the mobile-based applications segment is expected to lead the market, while the wearables segment is expected to grow considerably. Based on clinical practice, the monitoring segment is the largest, while the diagnostic segment is projected to witness substantial revenue growth over the forecast period. Based on end-use, the healthcare providers segment is expected to lead the market, followed by the healthcare companies segment. Based on region, North America is projected to dominate the global market during the estimated period, followed by Europe. Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.zionmarketresearch.com/custom/9582 3. Key Market Drivers Rising Global Burden of Mental Health Disorders The World Health Organization (WHO) estimates that one in eight people worldwide lives with a mental disorder, creating a massive need for early detection and continuous monitoring. Technological Advancements in Digital Health AI and machine learning (ML) enhance predictive accuracy in psychiatric assessments. Shift Toward Remote & Continuous Monitoring Post-pandemic telemedicine adoption supports remote mental health tracking. Growing Investments & Partnerships Tech giants, startups, and healthcare providers are collaborating to integrate biomarkers into mental health treatment plans. Regulatory Support for Digital Therapeutics (DTx) Approvals by bodies like the U.S. FDA are increasing confidence in digital biomarkers. 4. Market Restraints Privacy & Data Security Concerns Mental health data is highly sensitive, requiring stringent cybersecurity. Lack of Standardized Validation Methods No universal framework for validating psychiatric biomarkers. Digital Divide & Access Limitations Limited access to smartphones/wearables in rural or low-income regions. 5. Opportunities Integration with Wearables & IoT Devices Expanding applications in home-based mental health care. AI-Powered Predictive Psychiatry Early intervention potential through continuous behavior tracking. Expanding Applications in Corporate Wellness Programs Employers increasingly adopting mental health tech to improve workplace productivity. Emerging Markets Countries in Asia-Pacific, Middle East, and Latin America have large untapped populations with rising smartphone penetration. Inquiry For Buying- https://www.zionmarketresearch.com/inquiry/psychiatric-digital-biomarkers-market 6. Competitive Landscape The key players profiled in the global psychiatric digital biomarkers market include: Mindstrong Health Akili Interactive Pear Therapeutics Cognoa Koa Health Quartet Health Headspace Health Spring Health Ginger Behavioral Signals Joon Health Empatica Otsuka Digital Health Neurotrack Technologies NeuroFlow Key Strategies: Integration with digital therapeutics platforms. Partnerships with psychiatric research institutions. AI-driven personalization of treatment recommendations. 7. Regional Market Size & Forecast (2024–2034) 7.1 North America 2024 Value: $2.90 billion 2034 Value: $10.60 billion CAGR (2025–2034): 13.8 % Market Insights: The U.S. leads due to strong digital health infrastructure, high awareness, and supportive reimbursement policies. Canada's market is expanding rapidly, with government-backed mental health initiatives. 7.2 Europe 2024 Value: $1.40 billion 2034 Value: $5.70 billion CAGR (2025–2034): 15.1 % Market Insights: Germany, the UK, and France dominate due to robust healthcare systems and mental health reforms. The EU's Digital Health Strategy is accelerating adoption. 7.3 Asia-Pacific (APAC) 2024 Value: $1.20 billion 2034 Value: $6.80 billion CAGR (2025–2034): 18.7 % Market Insights: China and India are emerging hotspots due to rising smartphone penetration and mental health awareness. Japan and South Korea lead in integrating AI-driven biomarkers into psychiatric care. 7.4 Middle East & Africa (MEA) 2024 Value: $0.50 billion 2034 Value: $1.90 billion CAGR (2025–2034): 14.4 % Market Insights: UAE and Saudi Arabia are investing heavily in digital healthcare platforms. South Africa's adoption is driven by public-private partnerships in mental health services. 7.5 Latin America 2024 Value: $0.40 billion 2034 Value: $1.60 billion CAGR (2025–2034): 15.0 % Market Insights: Brazil leads due to growing demand for telepsychiatry. Mexico and Chile show increasing integration of digital biomarkers in clinical practice. 8. Market Trends Voice & Speech Biomarkers for Depression Detection AI algorithms analyzing tone, pitch, and pauses. Facial Expression Analysis in Schizophrenia & Autism Computer vision tools detecting microexpressions. Sleep Pattern Monitoring via Wearables Correlation between sleep quality and psychiatric disorders. Gamified Cognitive Behavioral Therapy (CBT) Interactive digital tools with embedded biomarker tracking. Blockchain for Mental Health Data Security Ensuring secure, tamper-proof patient data. 9. Conclusion The psychiatric digital biomarkers market is entering a high-growth phase with transformative potential for early diagnosis, personalized therapy, and continuous monitoring. North America will remain the largest market, fueled by advanced healthcare systems and strong funding. Asia-Pacific will witness the fastest growth due to rapid digital adoption and government-led mental health programs. Integration of AI, wearable devices, and telepsychiatry will define the future competitive landscape. Companies that focus on developing validated, secure, and user-friendly psychiatric biomarker platforms will be best positioned to dominate this expanding industry. More Trending Reports by Zion Market Research - Mass Spectrometry Market Dental Insurance Market Browse Other Related Research Reports from Zion Market Research- Blood Banking Devices Market By Product (Blood Processing Equipment, Blood Collection Equipment, and Blood Storage Equipment), By Functionality (Hospitals and Blood Banks), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/blood-banking-devices-market Egg Donation Market By Service Type (Fresh Egg Donation, Frozen Egg Donation, Egg Sharing Programs, and Anonymous Donation), By Application (In Vitro Fertilization, Fertility Preservation, Genetic Disorder Prevention, and Age-Related Infertility), By Distribution Channel (Fertility Clinics, Reproductive Centers, Hospitals, and Online Platforms), By End-User (Women Above 35, Couples with Genetic Disorders, Cancer Patients, and LGBTQ Community), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/egg-donation-market Physical Therapy Market By Therapy Type (Orthopedic Physical Therapy, Geriatric Physical Therapy, Neurological Physical Therapy, Cardiopulmonary and Pulmonary Physical Therapy, and Others), By Age Group (Pediatrics, Adults, Elderly), By End-Use (Hospitals and Clinics Community Centers, Sports Centers, Convalescent Homes, Schools and Sports Academies, and Others), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/physical-therapy-market Bakuchiol Market By Product Type (Pure Bakuchiol Extract, Bakuchiol Blends, Synthetic Bakuchiol, and Encapsulated Bakuchiol), By Application (Skincare Products, Anti-aging Formulations, Cosmetic Treatments, and Pharmaceutical Applications), By Distribution Channel (Online Retailers, Beauty Stores, Pharmacies, and Professional Channels), By End-User (Individual Consumers, Beauty Professionals, Dermatology Clinics, and Cosmetic Manufacturers), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/bakuchiol-market Prosthetic Disc Nucleus Market By Product Type (Hydrogel-Based Prosthetic Disc Nucleus, Polymer-Based Prosthetic Disc Nucleus, Metal-Based Prosthetic Disc Nucleus, and Composite Material Prosthetic Disc Nucleus), By Application (Degenerative Disc Disease, Herniated Disc, Disc Protrusion, and Spinal Stenosis), By Distribution Channel (Hospitals, Specialty Spine Centers, Ambulatory Surgical Centers, and Medical Device Distributors), By End-User (Orthopedic Surgeons, Neurosurgeons, Pain Management Specialists, and Rehabilitation Centers), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/prosthetic-disc-nucleus-market Oncology Molecular Diagnostic Market By Technology Type (Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, and Immunohistochemistry), By Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Blood Cancer), By Sample Type (Tissue Samples, Blood Samples, Urine Samples, and Other Biological Samples), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes, and Cancer Centers), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/oncology-molecular-diagnostic-market Mobile C Arms Market By Product Type (Mini C-arms, Full Size C-arms, and Others), By Application (Cardiology, Gastroenterology, Neurology, Orthopedics and Trauma, Oncology, and Others), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), and Specialty Clinics), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2025 - 2034- https://www.zionmarketresearch.com/report/mobile-c-arms-market Deepak Rupnar Zion Market Research richard@zionmarketresearch.com Visit us on social media: LinkedIn Instagram Facebook YouTube X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Pear Therapeutics Frequently Asked Questions (FAQ)
When was Pear Therapeutics founded?
Pear Therapeutics was founded in 2013.
Where is Pear Therapeutics's headquarters?
Pear Therapeutics's headquarters is located at 200 State Street, Boston.
What is Pear Therapeutics's latest funding round?
Pear Therapeutics's latest funding round is Asset Sale.
How much did Pear Therapeutics raise?
Pear Therapeutics raised a total of $334.94M.
Who are the investors of Pear Therapeutics?
Investors of Pear Therapeutics include Click Therapeutics, Nox Health, Harvest Bio, WELT, SoftBank and 18 more.
Who are Pear Therapeutics's competitors?
Competitors of Pear Therapeutics include Click Therapeutics, Cara Care, Lionrock, Akili Interactive, Valera Health and 7 more.
Loading...
Compare Pear Therapeutics to Competitors

Lyra Health operates in workforce mental health care within the health benefits industry. The company provides a digital platform that connects employees to mental health providers and tools, utilizing artificial intelligence (AI) for provider matching and offering evidence-based support. Lyra Health serves employers seeking to provide mental health benefits and support employee well-being. It was founded in 2015 and is based in Burlingame, California.

DynamiCare Health is a digital platform that specializes in substance use recovery within the healthcare sector. The company offers a digital recovery platform that provides remote substance testing, recovery coaching, and financial incentives for maintaining sobriety. DynamiCare Health primarily serves individuals seeking support for addiction recovery. It was founded in 2016 and is based in Boston, Massachusetts.

Mobio Interactive specializes in digital therapeutics and remote patient monitoring within the mental healthcare sector. The company offers an AI-native mobile platform that uses proprietary technologies to measure and treat mental health conditions, providing personalized therapy based on objective biomarkers. The platform primarily serves health systems, pharmaceutical companies, and insurance payors. It was founded in 2015 and is based in Singapore.

Pivot is a digital health company that focuses on tobacco cessation and behavioral change within the healthcare sector. The company offers a comprehensive suite of solutions, including digital programs, mobile applications, and personalized coaching designed to help individuals quit tobacco and improve their well-being. Pivot primarily serves employers, health plans, consultants, and brokers looking to integrate wellness solutions into their offerings. It was founded in 2015 and is based in San Carlos, California.

Monument is an online platform that specializes in alcohol treatment and recovery services. The company offers a range of services, including virtual support groups, therapy, and medication management, to assist individuals in reducing or stopping alcohol consumption. Monument's treatment options are accessible online, providing a flexible and supportive environment for those seeking help with alcohol dependence. It was founded in 2018 and is based in New York, New York.

Marigold Health is a company that provides peer support for mental health and substance use recovery within the behavioral health sector. The company has a social network where individuals can engage in peer support groups, access wellness and goal planning tools, and participate in theme-based chat groups. Marigold Health serves the behavioral health and substance use recovery sectors and works with existing care teams. It was founded in 2017 and is based in Boston, Massachusetts.
Loading...